The purpose of the study is to determine whether an experimental drug called GV20-0251 is safe and tolerable in patients with solid tumors that have not been successfully treated with standard therapies. GV20-0251 is a monoclonal antibody, which is a type of protein made in a laboratory; it will be given as an injection. The study will be conducted in two parts: Part A and Part B. The purpose of Part A is to determine the dose level to be studied in Part B. The purpose of Part B is to further study the safety and activity of GV20 0251 administered as an IV infusion in certain tumor types at the selected dose levels from Part A. Researchers will also conduct laboratory tests and/or measure tumor changes during Part B.
What is the full name of this clinical trial?
GV20-0251-100: An Open-Label Study of GV20-0251 in Patients with Advanced and/or Refractory Solid Tumor Malignancies